Telma MCT 50/6.25 mg Tablet

Telma MCT 50/6.25 mg Tablet is an hypertensive medication which is used in the treatment of high blood pressure and reduce the risk of heart attacks, stroke and cardiovascular complications.

Its active ingredient is Chlorthalidone in 6.25mg composition + Metoprolol Succinate in 50mg concentration + Telmisartan in 40mg concentration. The medicine is classified as a combination of a diuretic, a beta-blocker, and an angiotensin II receptor blocker (ARB). Consult to the healthcare professional before using the medication to ensure safe and effective treatment.

Manage high blood pressure

Every medication has certain side effects which are manageable with various treatments. Consult the healthcare professional if any of these symptoms persist while using Telma MCT 50/6.25 mg Tablet:

• Tiredness

• Feeling sleepy

• Headaches

• Back pain

• Difficulty in breathing

• Stomach upset

• Nausea

• Muscle pain

• Swelling of ankles and feet

• Dizziness

• vision change

• palpitation

• Fever

• Increased potassium level

Telma MCT 50/6.25 mg Tablet dose and duration are correctly recommended by the healthcare professional. Take the medication with food to improve the effectiveness of the treatment.

Never double up the medication on the missed one as this may cause complications during the treatment. Always follow the recommended dosage to ensure safe and effective treatment.

Telma MCT 50/6.25 mg Tablet contains three drugs including Telmisartan that relaxes blood vessels or improving blood flow, Metoprolol reduces heart rate and decreases the workload on the heart while Chlorthalidone removes excess salt or water from the body. Together, these medicines provide stronger and more consistent blood pressure control.

• Carter, B. L., Ernst, M. E., & Cohen, J. D. (2004). Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension, 43(1), 4-9.
  
• Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021). Chlorthalidone for hypertension in advanced chronic kidney disease. New England Journal of Medicine, 385(27), 2507-2519.
  
• Papadopoulos, D. P., & Papademetriou, V. (2009). Metoprolol succinate combination in the treatment of hypertension. Angiology, 60(5), 608-613.
  
• Wikstrand, J., Andersson, B., Kendall, M. J., Stanbrook, H., & Klibaner, M. (2003). Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. Journal of cardiovascular pharmacology, 41(2), 151-157.
  
• McClellan, K. J., & Markham, A. (1998). Telmisartan. Drugs, 56(6).​